{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:31:20Z","timestamp":1788993080121,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.schres.2022.07.014","type":"journal-article","created":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T05:37:02Z","timestamp":1659591422000},"page":"35-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Overactive, aggressive, disruptive and agitated behavior associated with the use of psychotropic medications in schizophrenia"],"prefix":"10.1016","volume":"248","author":[{"given":"Maria Fagerbakke","family":"Str\u00f8mme","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoffer","family":"Bartz-Johannesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rune Andreas","family":"Kroken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Mehlum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Johnsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.schres.2022.07.014_bb0005","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/bcpt.13384","article-title":"Polypharmacy in schizophrenia","volume":"126","author":"Baandrup","year":"2020","journal-title":"Basic Clin Pharmacol Toxicol."},{"issue":"2","key":"10.1016\/j.schres.2022.07.014_bb0010","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/YCO.0b013e32835d9efb","article-title":"Polypharmacy for schizophrenia","volume":"26","author":"Ballon","year":"2013","journal-title":"Curr Opin Psychiatry."},{"issue":"3","key":"10.1016\/j.schres.2022.07.014_bb0015","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.encep.2016.02.006","article-title":"Lithium and suicide prevention in bipolar disorder","volume":"42","author":"Benard","year":"2016","journal-title":"Enc\u00e9phale"},{"issue":"3","key":"10.1016\/j.schres.2022.07.014_bb0020","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00213-012-2668-2","article-title":"Antidepressants and lethal violence in the Netherlands 1994\u20132008","volume":"222","author":"Bouvy","year":"2012","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.schres.2022.07.014_bb0025","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1177\/104012371702900203","article-title":"Biological treatment of acute agitation or aggression with schizophrenia or bipolar disorder in the inpatient setting","volume":"29","author":"Correll","year":"2017","journal-title":"Ann. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2022.07.014_bb0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/yd.23319960203","article-title":"Assessing substance use disorder in persons with severe mental illness","volume":"70","author":"Drake","year":"1996","journal-title":"New Dir. Ment. Health Serv."},{"issue":"8","key":"10.1016\/j.schres.2022.07.014_bb0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000120","article-title":"Schizophrenia and violence: systematic review and meta-analysis","volume":"6","author":"Fazel","year":"2009","journal-title":"PLoS Med."},{"issue":"9949","key":"10.1016\/j.schres.2022.07.014_bb0040","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0140-6736(14)60379-2","article-title":"Antipsychotics, mood stabilisers, and risk of violent crime","volume":"384","author":"Fazel","year":"2014","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.schres.2022.07.014_bb0045","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00213-015-4167-8","article-title":"Medication and aggressiveness in real-world schizophrenia. Results from the FACE-SZ dataset","volume":"233","author":"Fond","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"issue":"9","key":"10.1016\/j.schres.2022.07.014_bb0050","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1017\/S146114571100201X","article-title":"A systematic review of the evidence of clozapine's anti-aggressive effects","volume":"15","author":"Frogley","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1\u20132","key":"10.1016\/j.schres.2022.07.014_bb0055","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.schres.2015.07.015","article-title":"Risk factors for sudden cardiac death among patients with schizophrenia","volume":"168","author":"Hou","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2022.07.014_bb0060","article-title":"Antiepileptics for aggression and associated impulsivity","volume":"2","author":"Huband","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"10.1016\/j.schres.2022.07.014_bb0065","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1177\/2045125314545614","article-title":"Time to discontinuation of antipsychotic drugs in a schizophrenia cohort: influence of current treatment strategies","volume":"4","author":"Kroken","year":"2014","journal-title":"Ther. Adv. Psychopharmacol."},{"issue":"Suppl. 5","key":"10.1016\/j.schres.2022.07.014_bb0070","first-page":"3","article-title":"Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia","volume":"67","author":"Leucht","year":"2006","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2022.07.014_bb0075","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/schbul\/sbm159","article-title":"Methodological issues in current antipsychotic drug trials","volume":"34","author":"Leucht","year":"2008","journal-title":"Schizophr. Bull."},{"issue":"Suppl. 1","key":"10.1016\/j.schres.2022.07.014_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1092852915000838","article-title":"The clinical challenges of akathisia","volume":"20","author":"Lohr","year":"2015","journal-title":"CNS Spectr."},{"issue":"1\u20133","key":"10.1016\/j.schres.2022.07.014_bb0085","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.schres.2007.09.009","article-title":"What is specific to suicide in schizophrenia disorder? Demographic, clinical and behavioural dimensions","volume":"98","author":"McGirr","year":"2008","journal-title":"Schizophr. Res."},{"issue":"12","key":"10.1016\/j.schres.2022.07.014_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015337","article-title":"Prescription drugs associated with reports of violence towards others","volume":"5","author":"Moore","year":"2010","journal-title":"PLoS One"},{"issue":"1\u20133","key":"10.1016\/j.schres.2022.07.014_bb0095","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.schres.2007.04.035","article-title":"Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia","volume":"98","author":"Mullins","year":"2008","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.schres.2022.07.014_bb0100","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.psychres.2008.03.018","article-title":"Completed suicide in schizophrenia: evidence from a case-control study","volume":"167","author":"Pompili","year":"2009","journal-title":"Psychiatry Res."},{"issue":"5","key":"10.1016\/j.schres.2022.07.014_bb0105","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00228-020-02830-2","article-title":"Use of antidepressants and mood stabilizers in persons with first-episode schizophrenia","volume":"76","author":"Puranen","year":"2020","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.schres.2022.07.014_bb0110","article-title":"Associations between individual antipsychotics and the risk of arrests and convictions of violent and other crime: a nationwide within-individual study of 74 925 persons","volume":"1\u20139","author":"Sariaslan","year":"2021","journal-title":"Psychol. Med."},{"issue":"5","key":"10.1016\/j.schres.2022.07.014_bb0115","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/schbul\/sbr090","article-title":"Aggression in schizophrenia","volume":"37","author":"Serper","year":"2011","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2022.07.014_bb0120","article-title":"Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports","volume":"352","author":"Sharma","year":"2016","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.schres.2022.07.014_bb0125","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/00005053-199901000-00003","article-title":"Suicide in patients hospitalized for schizophrenia: 1913\u20131940","volume":"187","author":"Stephens","year":"1999","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.schres.2022.07.014_bb0130","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2021.07.009","article-title":"Mortality and non-use of antipsychotic drugs after acute admission in schizophrenia: a prospective total-cohort study","volume":"235","author":"Stromme","year":"2021","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2022.07.014_bb0135","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/JCP.0000000000001497","article-title":"Use of benzodiazepines and antipsychotic drugs are inversely associated with acute readmission risk in schizophrenia","volume":"42","author":"Stromme","year":"2022","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.schres.2022.07.014_bb0140","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/acps.13208","article-title":"Adherence to clozapine vs. Other antipsychotics in schizophrenia","volume":"142","author":"Takeuchi","year":"2020","journal-title":"Acta Psychiatr. Scand."},{"issue":"2","key":"10.1016\/j.schres.2022.07.014_bb0145","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/wps.20220","article-title":"Psychotropic drugs and homicide: a prospective cohort study from Finland","volume":"14","author":"Tiihonen","year":"2015","journal-title":"World Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2022.07.014_bb0150","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/schbul\/sbr057","article-title":"Stigma and violence: isn't it time to connect the dots?","volume":"37","author":"Torrey","year":"2011","journal-title":"Schizophr. Bull."},{"issue":"5","key":"10.1016\/j.schres.2022.07.014_bb0155","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/arclin\/acy084","article-title":"ICD-10-CM diagnosis coding for neuropsychological assessment","volume":"34","author":"Uysal","year":"2019","journal-title":"Arch. Clin. Neuropsychol."},{"key":"10.1016\/j.schres.2022.07.014_bb0160","series-title":"Evidence-based Practice in the Field of Substance Abuse. A Book of Readings","author":"Van Wormer","year":"2009"},{"issue":"1","key":"10.1016\/j.schres.2022.07.014_bb0165","first-page":"24","article-title":"Violence in schizophrenia and bipolar disorder","volume":"25","author":"Volavka","year":"2013","journal-title":"Psychiatr. Danub."},{"issue":"8","key":"10.1016\/j.schres.2022.07.014_bb0170","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/j.1742-1241.2008.01797.x","article-title":"Heterogeneity of violence in schizophrenia and implications for long-term treatment","volume":"62","author":"Volavka","year":"2008","journal-title":"Int. J. Clin. Pract."},{"issue":"6","key":"10.1016\/j.schres.2022.07.014_bb0175","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1093\/schbul\/sbaa060","article-title":"Clozapine combination and augmentation strategies in patients with schizophrenia -recommendations from an international expert survey among the treatment response and resistance in psychosis (TRRIP) working group","volume":"46","author":"Wagner","year":"2020","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.schres.2022.07.014_bb0180","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1034\/j.1600-0447.2001.00357.x","article-title":"Selective serotonin reuptake inhibitors and violence: a review of the available evidence","volume":"104","author":"Walsh","year":"2001","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2022.07.014_bb0185","article-title":"Valproate for schizophrenia","volume":"11","author":"Wang","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"10.1016\/j.schres.2022.07.014_bb9000","first-page":"150","volume":"8","author":"Whiting","year":"2021","journal-title":"Violence and mental disorders: a structured review of associations by individual diagnoses, risk factors, and risk assessment"},{"key":"10.1016\/j.schres.2022.07.014_bb0190","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1192\/bjp.172.1.11","article-title":"Health of the nation outcome scales (HoNOS).Research and development","volume":"172","author":"Wing","year":"1998","journal-title":"Br J Psychiatry"},{"issue":"Suppl. 3","key":"10.1016\/j.schres.2022.07.014_bb0195","first-page":"345","article-title":"Benzodiazepines in combination with antipsychotic drugs for schizophrenia: GABA-ergic targeted therapy","volume":"29","author":"Wlodarczyk","year":"2017","journal-title":"Psychiatr. Danub."},{"issue":"10","key":"10.1016\/j.schres.2022.07.014_bb0200","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1177\/0300060518786634","article-title":"Epidemiology of schizophrenia and risk factors of schizophrenia-associated aggression from 2011 to 2015","volume":"46","author":"Wu","year":"2018","journal-title":"J. Int. Med. Res."},{"issue":"5","key":"10.1016\/j.schres.2022.07.014_bb0205","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/schbul\/sby056","article-title":"Benzodiazepines for psychosis-induced aggression or agitation","volume":"44","author":"Zaman","year":"2018","journal-title":"Schizophr. Bull."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996422002869?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996422002869?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:48:22Z","timestamp":1760298502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996422002869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":42,"alternative-id":["S0920996422002869"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2022.07.014","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overactive, aggressive, disruptive and agitated behavior associated with the use of psychotropic medications in schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2022.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}